SCHOTT Pharma AG & Co. KGaA

Frankfurt Stock Exchange 1SXP.F

SCHOTT Pharma AG & Co. KGaA EBITDA for the year ending September 30, 2024: USD 292.21 M

SCHOTT Pharma AG & Co. KGaA EBITDA is USD 292.21 M for the year ending September 30, 2024, a 21.40% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • SCHOTT Pharma AG & Co. KGaA EBITDA for the year ending September 30, 2023 was USD 240.71 M, a 20.94% change year over year.
  • SCHOTT Pharma AG & Co. KGaA EBITDA for the year ending September 30, 2022 was USD 199.03 M, a 16.59% change year over year.
  • SCHOTT Pharma AG & Co. KGaA EBITDA for the year ending September 30, 2021 was USD 170.71 M, a 16.33% change year over year.
  • SCHOTT Pharma AG & Co. KGaA EBITDA for the year ending September 30, 2020 was USD 146.74 M.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
Frankfurt Stock Exchange: 1SXP.F

SCHOTT Pharma AG & Co. KGaA

CEO Mr. Andreas Reisse
IPO Date Sept. 26, 2023
Location Germany
Headquarters Hattenbergstrasse 10
Employees 4,681
Sector Health Care
Industries
Description

SCHOTT Pharma AG & Co. KGaA develops, produces, and sells drug containment solutions and delivery systems for injectable drugs to the pharmaceutical and biotechnology industries worldwide. The company offers polymer and glass syringes, ampoules, vials, and cartridges. Its syringe products include syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; and SCHOTT TOPPAC unique, a polymer container. The company's cartridge products comprise cartriQ, a pharmaceutical glass cartridge for peptide and protein-based injectables; cartriQ Large Volume, a pharmaceutical glass cartridge for large-volume injectables; Cartridges Double Chamber, a pharmaceutical glass cartridge for lyophilized drugs; Cartridges Break Resistant, a pharmaceutical glass cartridge; and TopLine and StandardLine cartridges. Its vial products include adaptiQ, a pharmaceutical glass vial for injectables; EVERIC pure, a pharmaceutical glass vial for unmatched drug stability; EVERIC care, a pharmaceutical glass vial for a pH range; EVERIC strong & smooth, a pharmaceutical glass vial for the filling line performance; SCHOTT Type I plus, a pharmaceutical glass vial for drug formulations; SCHOTT TopLyo, a pharmaceutical glass vial to avoid fogging for lyophilized drugs; and TopLine and StandardLine vials. Its ampoule products comprise Ampoules easyOPC, a pharmaceutical glass ampoule for ampoule opening; Ampoules Anti-Counterfeiting, a pharmaceutical glass ampoule for protection against drug counterfeiting; and StandardLine ampoules. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.

StockViz Staff

January 15, 2025

Any question? Send us an email